FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
SOUTH PLAINFIELD, N.J., March 16, 2017 -- Advanced Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today that its PGxOne™ Plus has received New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) approval for its 50 gene PGxOne™ Plus pharmacogenomics test. Admera had previously been approved by NYSDOH CLEP to offer its PGxOne™ Plus 25 gene version in the state of New York. With this approval, the updated PGxOne™ Plus 50 gene test is available in all 50 states.
PGxOne™ Plus is a Next Generation Sequencing (NGS) based test that predicts how a patient will respond to drug therapy based on their individual genetic makeup. Therapeutic areas include, but are not limited to, cardiology, psychiatry, pain management, and oncology. Examples of recommendations provided in the report are: consider alternatives (when specific drugs should be avoided), dosing adjustments, use with caution, or normal response expected.
“While we already had an earlier version of the PGxOne™ Plus test available to New York residents, we are thrilled to be able to offer them the full panel that interrogates nearly 200 different variants and provides clinically relevant recommendations for over 220 associated drugs,” said Guanghui Hu, PhD, President and CEO of Admera Health. He went on, “CLEP approval is a highly cherished milestone in the laboratory field and we are looking forward to our next submission.”
In addition to PGx testing, Admera Health offers clinical testing for the risk assessment and diagnosis of inherited cardiovascular diseases, cancer supportive therapy, and tumor profiling to guide selection of targeted therapies.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
